MedPath

Aortoiliac Stenosis in Kidney Transplantation

Completed
Conditions
Peripheral Arterial Disease
Kidney Transplant Failure
Aorto-Iliac Arterial Stenosis
Registration Number
NCT06020534
Lead Sponsor
Erasmus Medical Center
Brief Summary

The impact of aortoiliac stenosis on kidney transplant patients remains unclear. This study aims to investigate the safety and efficacy of kidney transplantation in patients with aortoiliac stenosis.

Detailed Description

Kidney transplantation is the optimal treatment for end-stage renal disease (ESRD). Unfortunately, not all ESRD patients are eligible for kidney transplantation. Aortoiliac stenosis, an increasingly common type of peripheral arterial disease in ESRD patients, is considered as relative contra-indication for kidney transplantation. There are several reasons for concern, such as the complexity of the vascular anastomosis and inferior life expectancy. Consequently, it is still debated whether patients with aortoiliac stenosis would benefit from kidney transplantation.

This study aimed to supplement current literature on the safety and efficacy of kidney transplantation in patients with aortoiliac stenosis. To achieve this, all patients undergoing kidney transplantation in Erasmus Medical Center between January 2010 and December 2020 were enrolled, and propensity score matching was used to minimize confounding factors. Additionally, long-term graft function was investigated to evaluate the impact of stenosis on graft function.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
655
Inclusion Criteria
  • Patients who underwent kidney transplantation in the Erasmus Medical Center between January 2010 and December 2020
Exclusion Criteria
  • Patients who were under 18 years at transplantation
  • Patients who underwent combined organ transplantation
  • Patients who had no follow-up

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Patient SurvivalFrom the date of kidney transplantation till death or data cut-off, whichever came first, assessed up to 10 years.

Patient survival was calculated based on all-cause death from the date of kidney transplantation till the end of follow-up (January, 2023), assessed up to 10 years.

Secondary Outcome Measures
NameTimeMethod
Death-censored Graft SurvivalFrom the date of kidney transplantation till death or data cut-off, whichever came first, assessed up to 10 years.

Death-censored graft survival was calculated based on death-censored graft failure, from the date of kidney transplantation till death or data cut-off, whichever came first, assessed up to 10 years.

Graft FunctionFrom the date of kidney transplantation till death or data cut-off, whichever came first, assessed up to 10 years.

Estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation at every post transplant year up to 10 years.

Trial Locations

Locations (1)

Yitian Fang

🇳🇱

Rotterdam, Zuid Holland, Netherlands

© Copyright 2025. All Rights Reserved by MedPath